Search
for
Sort by
Research 781–810 of 1000+
- S5 IS THE RADICAL PROSTATECTOMY THE BEST CHOICE FOR PATIENTS WITH LOCALLY ADVANCED PROSTATE CANCER?
- 1408 INDUCTION OF SECRETED WNT FACTOR WISP1/CCN4 BY HUMAN PROSTATE STROMAL CELLS BY MICROENVIORNMENTAL HYPOXIA
- 1406 DETECTION OF MEMBRANE ANDROGEN-BINDING SITE IN LIVING RAT PROSTATE AND EVALUATION OF ITS ROLE IN PROSTATE BLOOD FLOW REGULATION
- S89 Clinical outcomes of high risk prostate adenocarcinoma (T3 and Gleason score ≥8)
- Urological Oncology: Prostate Cancer
- Prostate cancer update: 2007
- Body Mass Index is Associated with Increased Risk of aggressive and Decreased Risk of Non-aggressive Prostate Cancer
- Prostate Specific Antigen Levels in Diabetic and Non-Diabetic Men from the 2001–2002 National Health and Nutrition Examination Survey
- IMPLICAÇÕES DA TOMA CRÓNICA DA FINASTERIDE PARA A ALOPÉCIA ANDROGENÉTICA NO CARCINOMA DA PRÓSTATA
- Role of serum androgens and prostate-specific antigen levels in males with androgenetic alopecia
- Association between degrees of alopecia and prostate specific antigen level in men with androgenetic alopecia
- P152 : Association between degrees of alopecia and prostate specific antigen level in men with androgenetic alopecia
- Faculty Opinions recommendation of Androgenetic alopecia and risk of prostate cancer: a systematic review and meta-analysis.
- 341 ANDROGENETIC ALOPECIA AT VARIOUS AGES AND PROSTATE CANCER RISK IN AN EQUAL ACCESS MULTIETHNIC CASE CONTROL SERIES OF VETERANS
- The Long-Term Effect of Doxazosin, Finasteride, and Combination Therapy on the Clinical Progression of Benign Prostatic Hyperplasia
- Marked Suppression of Dihydrotestosterone in Men with Benign Prostatic Hyperplasia by Dutasteride, a Dual 5α-Reductase Inhibitor
- 5α-reductase activity in the prostate
- Three-Month Treatment With a Long-Acting Gonadotropin-Releasing Hormone Agonist of Patients With Benign Prostatic Hyperplasia: Effects on Tissue Androgen Concentration, 5<i>α</i>-Reductase Activity and Androgen Receptor Content*
- What do we know about phytotherapy of benign prostatic hyperplasia?
- Sexual dysfunction in subjects treated with inhibitors of 5α-reductase for benign prostatic hyperplasia: a comprehensive review and meta-analysis
- Association of Benign Prostatic Hyperplasia with Male Pattern Baldness
- Reduced levels of 5-α reductase 2 in adult prostate tissue and implications for BPH therapy
- 5α‐Reductase inhibitors and prostatic disease
- Finasteride and Erectile Dysfunction in Patients with Benign Prostatic Hyperplasia or Male Androgenetic Alopecia
- α-spinasterol from Melandrium firmum attenuates benign prostatic hyperplasia in a rat model
- Efficacy and safety of Finasteride (5 alpha-reductase inhibitor) monotherapy in patients with benign prostatic hyperplasia: A critical review of the literature
- Finasteride does not prevent bladder cancer: A secondary analysis of the Medical Therapy for Prostatic Symptoms Study
- Exploring the Inhibitory Potential of Phytosterols β-Sitosterol, Stigmasterol, and Campesterol on 5-Alpha Reductase Activity in the Human Prostate: An In Vitro and In Silico Approach
- The corpus cavernosum after treatment with dutasteride or finasteride: A histomorphometric study in a benign prostatic hyperplasia rodent model
- Development of prostate cancer in a patient with primary hypogonadism: intratumoural steroidogenesis in prostate cancer tissues